Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Clinical trial NCT04379596 · RECRUITING
Trial details
- NCT number
- NCT04379596
- Sponsor
- AstraZeneca
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-03
- Primary completion
- 2027-06-01
- Enrollment
- 450
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.